NCT04344379 Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus Status COMPLETED Phase PHASE3
NCT04341870 Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO Status SUSPENDED Phase PHASE2/PHASE3
NCT04341727 Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection Status TERMINATED Phase PHASE3
NCT04341207 Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients Status UNKNOWN Phase PHASE2
NCT04339816 Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial Status TERMINATED Phase PHASE3
NCT04338698 Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT Status COMPLETED Phase PHASE3
NCT04335552 Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection Status TERMINATED Phase PHASE2
NCT04334382 Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 Status UNKNOWN Phase PHASE3
NCT04332107 Azithromycin for COVID-19 Treatment in Outpatients Nationwide Status TERMINATED Phase PHASE3
NCT04332094 Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19) Status UNKNOWN Phase PHASE2
NCT04329832 Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 Status COMPLETED Phase PHASE2
NCT04322396 Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19 Status TERMINATED Phase PHASE2
NCT04319705 Anti-viral Effects of Azithromycin in Patients With Asthma and COPD Status UNKNOWN Phase PHASE4
NCT04310930 Finding the Optimal Regimen for Mycobacterium Abscessus Treatment Status RECRUITING Phase PHASE2/PHASE3
NCT04296383 Xiyanping Injection Combined With Azithromycin VS Azithromycin for Children With pneumoniaProtozoal Pneumonia Status UNKNOWN Phase NA
NCT04294641 Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease Status COMPLETED Phase PHASE2